Genetic Analysis of Pathways to Parkinson Disease  by Hardy, John
Neuron
PerspectiveGenetic Analysis of Pathways
to Parkinson DiseaseJohn Hardy1,*
1Reta Lilla Weston Laboratories and Department of Molecular Neuroscience, UCL Institute of Neurology, London WC1N 3BG, UK
*Correspondence: j.hardy@ion.ucl.ac.uk
DOI 10.1016/j.neuron.2010.10.014
In this review I outline the arguments as to whether we should consider Parkinson disease one or more than
one entity and discuss genetic findings from Mendelian and whole-genome association analysis in that
context. I discusswhat the demonstration of disease spread implies for our analysis of the genetic and epide-
miologic risk factors for disease and outline the surprising fact that we now have genetically identified on the
order of half our risk for developing the disease.
Open access under CC BY license.Wehave two goals in the genetic analysis of disease: the first is to
increase the accuracy of risk prediction, with an intention of
getting better at diagnosing the disease earlier and perhaps tar-
geting presymptomatic therapy; the second is to define the path-
ways that lead tocell deathso thatwecandesign approaches that
intervene in those pathways and act as mechanistic therapies.
In Parkinson disease, a neurodegenerative disorder affecting
movement and usually characterized by the presence of a-syn-
uclein containing Lewy bodies in damaged neurons, genetic
analysis has been remarkably successful, with many mendelian
loci already described, a common high-risk variant identified and
many common low-risk variants recently elucidated. This is
particularly remarkable because epidemiologic investigations
preceding the identification of the a-synuclein (SNCA) locus
consistently suggested that genes were unimportant in disease
etiology. As our knowledge of the disease has increased over
the last 15 years, the proportion of risk assigned to the environ-
ment has consistently decreased and, while associations with
environmental factors have been confirmed (such as that
showing a negative association with smoking), no environmental
risk factor with a convincing pathogenic role in the disease has
yet been described.
We and others have recently comprehensively reviewed the
identification of mendelian genes for Parkinson disease (Hardy
et al., 2009; Klein and Lohmann-Hedrich, 2007; Cookson and
Bandmann, 2010). Given this, my purpose in this review is to
discuss four issues:
1. To discuss whether all the identified genes relate to single
entity and what pathways have been identified as relevant
to disease.
2. To discuss how the identification of risk loci through
genome-wide association studies relate to the Mendelian
genes andwhether we should inevitably expect those low-
risk loci to encode proteins that map onto the same path-
ways as those identified through the identification of
Mendelian loci:
3. To discuss the implication of permissive templating (‘‘prio-
noid’’) behavior ofa-synuclein to theconceptofdisease risk
4. To discuss the proportion of risk for disease that has been
identified so far.Mendelian and High-Risk Loci for Parkinson Disease
Table 1 lists the loci at which pathogenic mutations lead to
parkinsonism (for references, see Hardy et al., 2009). These
include those loci traditionally noted as ‘‘Parkinson loci’’ as
well as others that are not, including MAPT, SCA2, SCA3,
and spastacsin, which can clinically present as Parkinson
disease but often is clinically distinct. In some diseases, most
clearly Alzheimer disease, the disease is defined by its
pathology. In Parkinson disease, the disease has been tradition-
ally defined clinically, but the vast majority of cases of disease
have the pathology of Lewy bodies (Hughes et al., 1993).
However, while the vast majority of idiopathic cases have Lewy
bodies, the genetic forms of the disease have variable patholo-
gies (Table 1). Thus part of my intention in this review is to ques-
tion how we should group the genetic loci if we are trying to
understand the pathogenesis of the disorder. Should we use
clinical criteria (in which case, all of the loci may stake a claim
as to involvement), or should we use pathological criteria, in
which case the number clearly involved is much smaller although
for many, the pathology has not been documented?
In Favor of Using Pathological Criteria
The major argument in favor of using pathological criteria for the
definition of disease is an analogy: in Alzheimer disease, the loci
identified for the disorder, APP, and the presenilins clearly map
into one pathway (Hardy and Selkoe, 2002): defining the disease
clinically would lead to confusion with a large series of other
genes (MAPT, PRNP, PGRN, etc.) being grouped with them.
A second argument is that both clinically and pathologically
the disease seems to spread along neuronal pathway. This
notion of the disease spreading has been most vividly captured
by the work of Braak and colleagues (Braak et al., 2003) and is
supported by the idea that misfolded synuclein acts as
a template for other synuclein to deposit upon (see below).
It is difficult to see how this templating pathogenesis could be
relevant to those forms of the disease without Lewy body
pathology.
Against Using Pathological Criteria: for Using
Clinical Criteria
There are several arguments against using pathological criteria.
First, the pathology of (for example) LRRK2 mutation carriers is
variable with the majority of cases having Lewy bodies, butNeuron 68, October 21, 2010 ª2010 Elsevier Inc. 201
Table 1. Mendelian Genes that Lead to Parkinsonism and Their Pathology
Locus Genes Clinical Features Pathology
Dominant
PARK1/4 a-Synuclein Typical PD but can sometimes have
a dementia presentation
Lewy bodies
PARK8 LRRK2 Typical PD Usually Lewy bodies: sometime tangles,
sometimes neither
FTDP-17 MAPT Most mutations have a dementia phenotype
but some have a typical PD presentation
Tau/tangle pathology
SCA3 Ataxin3 Usually ataxia in Europeans, but often
Parkinsonian especially in Africans
Probably not Lewy bodies.
Probably polyglutamine inclusions
SCA2 Ataxin2 Usually ataxia in Europeans, but often
Parkinsonian especially in Asians
Probably not Lewy bodies.
Probably polyglutamine inclusions
Recessive
PARK2 Parkin Very slowly progressive early onset disease
usually with sleep benefit
Usually not Lewy bodies
PARK6 PINK1 Usually very slowly progressive early onset
disease usually with sleep benefit
One case with Lewy bodies
PARK7 DJ-1 Little data, but seems similar to parkin Not known
PARK9 ATP13A2 Aggressive and complex parkinsonism with
many additional features
Not known
PARK14 PLA2G6 Aggressive and complex parkinsonism with
many additional features
Lewy bodies
SPG11 Spatacsin Usually spastic paraplegia but sometimes




Gaucher’s (1) locus GBA Typical PD Lewy bodies
Low-Risk Loci
SNCA Typical PD Lewy bodies
MAPT Lewy bodies (though tau pathology
not systematically assessed
LRRK2 Typical PD Lewy bodies
HLA Typical PD Lewy bodies
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prich et al., 2004). Second, a few compound heterozygote parkin
mutation cases (e.g., Farrer et al., 2010) and some clearly simple
heterozygous parkin and some, at least, PINK1 cases have been
reported to have typical Lewy body disease suggesting that the
pathogeneses of the two forms of the disease are not dissimilar
(Samaranch et al., 2010). Third, although mutations in MAPT
(microtubule-associated protein tau, or often referred to simply
as tau) lead to a disorder that can closely clinically resemble idio-
pathic Parkinson disease, the majority have a dementing
syndrome that is clearly different from Parkinson disease;
however, the MAPT/tau haplotype shows an association with
disease (see below) strongly suggesting that the pathogenic
cascades in the tauopathies must be related to those in the syn-
ucleinopathies.
A practical argument against using pathological criteria is
that for many syndromes, we do not know the underlying
pathology of many of the syndromes, and a lesson to be
drawn from the case of LRRK2 mutations is that pathology can
be variable.202 Neuron 68, October 21, 2010 ª2010 Elsevier Inc.Against Using Clinical Criteria
As Table 1 illustrates, there are many syndromes that can
masquerade as Parkinson disease, some of which (e.g., SCA2
and SCA3) almost certainly have different pathogenic
mechanisms since they are both polyglutamine repeat disorders.
Furthermore, there are clear phenotypic differences between the
diseases defined by their genetic etiology. As an example, the
Japanese clinicians who first identified PARK2 encoded disease
were clear that this was distinct from typical Parkinson disease,
with a very prolonged and benign disease duration, profound
dopamine sensitivity, and sleep benefit (Yamamura 2010);
PINK1 and possibly (Bonifati et al., 2005) DJ-1 and FBXO7
encoded diseases seem similar (Paisa´n-Ruiz et al., 2010). This
is clearly clinically different from typical idiopathic Parkinson
disease (see Hughes et al., 1993)
What Pathways Have Come out of the Analysis
of Mendelian Genes?
The pathway that has come most clearly out of the analysis of
the Mendelian genes is a mitochondrial damage repair pathway.
It is clear that parkin, an E3 ubiquitin ligase, and PINK1,
Neuron
Perspectiveamitochondrial kinase, are genetically in the same pathway (with
parkin downstream of PINK1) and that this pathway is involved in
the elimination of damagedmitochondria (Park et al., 2006; Clark
et al., 2006). DJ-1, and possibly FBX07, another ubiquitin ligase,
are also likely to be involved in mitochondrial physiology. DJ-1
has been shown to translocate to the mitochondria and exert
a protective effect on the application of oxidative stress
(Canet-Avile´s et al., 2004: see Cookson 2010). Whether the
products of these genes are also directly involved in the same
or different mitochondrial repair/elimination pathways is not yet
clear. But the likelihood that all these genes map onto mitochon-
drial pathways and all have rather similar clinical phenotypes
is striking (Paisa´n-Ruiz et al., 2010; Valente et al., 2004;
Yamamura 2010). It is notable that MPTP toxicity is also both
dopamine selective and mitochondrial (Langston 1989). Of
course, MPTP selectivity is largely explicable through dopamine
metabolism, but the clear impression is that dopamine and
possibly other catecholamine neurons are selectively sensitive
to mitochondrial damage (Schapira 2008; Dodson and Guo,
2007; Cookson and Bandmann, 2010).
A second pathway that is likely to be involved in Parkinson
disease clearly involves the lysosomes. Glucosecerebrosidase
and ATP13A2 are lysosomal enzymes (though the precise
function of the latter is not yet clear). While there are interactions
between lysosomal and mitochondrial metabolism (as there are
between any cellular compartments), whether there is or should
expected to be any close relationship between these loci and the
mitochondrial loci is not clear.
The two loci that all would agree are central to Parkinson
disease, SNCA and LRRK2, are, in many ways, the most myste-
rious. a-synuclein clearly has a role in synaptic release
(Cabin et al., 2002) and is related to the SNARE complex proteins
(Burre´ et al., 2010), and, as a kinase, LRRK2 is almost certainly
involved in signaling cascades (Dauer and Ho, 2010), probably
relating to cytoskeletal dynamics (MacLeod et al., 2006;
Meixner et al., 2010). While there is some evidence that LRRK2
and SNCA may have a role in the same pathway (Lin et al.,
2009), they do not appear to interact directly and their roles
have no obvious connection to either lysosomal or mitochondrial
metabolism.
Low-Risk Loci for Parkinson Disease
Genome-wide association studies (GWAS) have revolutionized
our efforts to find loci at which common, normal genetic vari-
ability contributes to disease risk. Since these findings, for all
diseases, are relatively new, we have little experience in concep-
tualizing what this common variability is and how it fits into the
jigsaw of pathogenesis. In general, most of the loci found by
this strategy are present in more than 5%of the population (allele
frequencies of > 10%) and, if you have the risk allele, increase
your risk of disease less than two fold over the population
average (have odds ratios OR < 2). As a comparator, possessing
a single APOE4 allele (present in 10% of the population)
increases your risk of Alzheimer disease about four-fold. The
majority of these low-risk loci for all diseases seem to mediate
their effect by altering gene expression rather than through
protein coding changes. In fact, there is an approximate relation-
ship that as the odds ratios at a locus increases the more likelythat the encoding gene will have a protein coding alteration at
its heart (Singleton et al., 2010).
In Parkinson disease GWAS, the fact that the SNCA locus was
the first to reach genome-wide significance is perhaps not
surprising (Simo´n-Sa´nchez et al., 2009) (since it had previously
been suggested on the basis of candidate gene analysis: Kru¨ger
et al., 1999) and this is consistent with the general suggestion
that genetic variability at the loci encoding deposited protein
influences the risk of disease (Singleton et al., 2004). For
instance, theMAPT locus is the most prominent locus for the
tangle diseases and the prion locus the most prominent locus
for Creutzfeldt-Jakob disease. Likewise, gene duplications at
SNCA cause familial Parkinson disease: gene duplications at
MAPT cause frontotemporal dementia and gene duplications
at APP cause Alzheimer disease (for references, see Singleton
et al., 2004). In the case of the SNCA locus, it seems likely that
those in the population who express about 10% more than the
average have an increase of developing Parkinson disease
increased by about 40% (Simo´n-Sa´nchez et al., 2009; Fuchs
et al., 2008). While this finding is intellectually satisfying, it does
not radically alter our view of the pathogenesis of disease,
although it does make it genetically clear that a-synuclein is
central to the pathogenesis in idiopathic disease.
The fact that MAPT is the second locus to come out of the
GWAS is more surprising, although it too had been previously
identified as a candidate gene (Golbe et al., 2010). While tau
pathology is sometimes found in Parkinson disease, it is not
pathognomic. Furthermore the haplotype that is associated
with Parkinson disease is distinct from that associated with the
tangle disorder, progressive supranuclear palsy (Vandrovcova
et al., 2009). Indeed, strictly, we cannot be sure that the associ-
ation is with tau since the large haplotype that is associated with
Parkinson disease has many other genes upon it (Fung et al.,
2005). Finally, although we do not understand the relationship
between the MAPT locus and Parkinson disease, it is worth
remembering that while LRRK2 mutations usually give rise to
a-synuclein pathology, they sometimes give rise to tangle
pathology (Zimprich et al., 2004) and that, while APP mutations
usually give rise to tangle pathology, they sometimes give rise
to Lewy body pathology (Hardy 1994). In other words, there
are at least three examples where there are genetic pathologic
connections between a-synuclein and tau.
The association between LRRK2 and sporadic disease seen in
GWAS is not yet understood. It is not clear whether the associa-
tion is driven by genetic variability in the expression of LRRK2
(which would imply that normal function of LRRK2was important
in disease etiology) or whether the effect is driven by some of the
relatively common pathogenic mutations among the samples
that have been used in the studies. LRRK2 is a very large gene
and by no means had all of the samples used in the studies
been sequenced. Thus, we cannot yet tell whether the LRRK2
finding in GWAS represents a new finding or a rediscovery of
an old one.
The identification of the HLA locus as reaching genome-wide
significance is of great interest (Hamza et al., 2010). It too had
been previously identified as a candidate locus for Parkinson
disease (Saiki et al., 2010), but its recognition as an important
locus for disease has profound implications both narrowly forNeuron 68, October 21, 2010 ª2010 Elsevier Inc. 203
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the identification of risk loci for late-onset neurodegenerative
disease. Similar to the recent GWAS pointing to the complement
cascade as contributing to risk of Alzheimer disease
(Harold et al., 2009; Lambert et al., 2009) and the identification
of complement H as the major risk locus for macular degenera-
tion (Klein et al., 2005), it points to the potential importance
of genetic variability in damage repair and clean up as influencing
risk for disease. In the case of Alzheimer disease and macular
degeneration, as well as Parkinson disease, the adaptive or
innate immune systems had previously been implicated in
disease pathology (McGeer et al., 1988; McGeer et al., 1989;
McGeer et al., 2005), though the precise role has not been clear.
From these findings, one might propose that, given
a pathogenic insult, at least some of these low-risk loci may
not actually be important for disease etiology, either in
triggering disease or disease progression or even in the path-
ways that initiate cell death, but rather are involved in the
clearing out of the detritus. If this turns out to be the case, it is
interesting to note that in the different diseases, different aspects
of the immune system appear to play more or less important
roles.
The Importance of Permissive Templating—‘‘Prionoid’’
Behavior—in the Pathogenesis of Parkinson Disease
Li and Kordower and their colleagues showed, in autopsy
studies of patients with Parkinson disease who had, clinically
successfully, received fetal dopmainergic grafts and survived
more than 10 years had developed Lewy bodies in those grafts.
This remarkable demonstration that grafted embryonic dopami-
nergic cells develop Lewy bodies after 10 years in the brain of
someone with Parkinson disease (Li et al., 2008; Kordower et al.,
2008) can be interpreted in two ways: first, that the environment
the cells are in is conducive to Lewy body formation in some
nonspecific way, or, alternatively, that Lewy body material from
the surrounding tissue has templated the pathology in the graft
neuron (Brundin et al., 2008). The latter interpretation is favored
by analogy (Hardy 2005), not only with prion diseases, but also
by analogy with experimental work on both Ab and tau pathology
spread (Meyer-Luehmann et al., 2006; Clavaguera et al., 2009;
Frost and Diamond, 2010). In addition, direct cell to cell spread
of a-synuclein aggregation has been demonstrated in vitro.
These findings are, of course, completely consistent with the
view of these diseases propounded by Braak and colleagues
(Braak and Braak, 1998; Braak et al., 2003) who has proposed
that both Alzheimer and Parkinson disease spread within the
brain in a fairly consistent manner
These observations about how AD and PD pathology spread
within the brain, across regions, imply that disease initiation
need only to occur at a single site. If initiation need only occur
once, then while factors that increase its likelihood will be risk
factors (such as an increase in the concentration of its constit-
uent protein), its precise initiation will be stochastic and not
predictable and, therefore, may be due to stochastic events
rather than predictable ones. The clear corollary of this sugges-
tion is it may not be possible to completely predict who will get
Parkinson disease (or the other diseases for which this is true):
identical twins who live identical lives may have different204 Neuron 68, October 21, 2010 ª2010 Elsevier Inc.outcomes vis-a`-vis Parkinson disease because of stochastic
initiation events.
How Much Risk Has Been Found?
As we continue our genetic analysis, we are finding more
and more alleles at several genes that increase our risk of
disease. One important question is how much of the risk for
disease have we found? If we could take all the risk alleles
for disease out of circulation, how much would we reduce the
incidence of the disease? The amount of risk for Parkinson
disease we have found varies enormously from population to
population and the amount accounted for by different risk loci
also varies across populations. Among the Ashkenazim, a very
large proportion of risk, perhaps 40%, is accounted for by
LRRK2 (G2019S) and GBA mutations (Ozelius et al., 2006;
Sidransky et al., 2009); in Arab populations too, LRRK2
G2019S is an important factor (Lesage et al., 2006). In East Asian
populations, there are a number of common LRRK2 variants that
considerably alter risk (Mata et al., 2005; Ross et al., 2008).
Together, coding variability at LRRK2 explains about 10% of
risk in these populations (Tan et al., 2010). In outbred European
populations, the proportion of risk due to coding variability in
LRRK2 and GBA is less but still appreciable at about 8%
(Gilks et al., 2005; Sidransky et al., 2009). Parkin and to a lesser
extent PINK1 mutations are common in early-onset disease and
may explain about 50%of the disease with an age at onset under
40: but this is probably only of the order of 1%–2%of the disease
overall (Iba´n˜ez et al., 2006). Thus, Mendelian and identified
high-risk loci explain between 10% and 40% of risk in most
populations so far assessed.
Working out the proportion of risk encoded by common
low-risk loci is less straightforward, but it seems that in European
populations, the SNCA, MAPT, and HLA loci each explain of the
order of 10% of risk (Simo´n-Sa´nchez et al., 2009; Hamza et al.,
2010). These figures are, of course, derived from mainly clinic-
based series of cases and are not population based, an
approach that generally leads to an overestimate of the amount
of risk that has been identified. However, these risk calculations
also only take into account themost common variant identified at
each locus, and, undoubtedly, further analysis will identify other
risk variants at each locus.
While all of these calculations are, of necessity, back-of-enve-
lope calculations, they imply that genetic analysis has already
identified of the order of half of the attributable risk of getting
Parkinson disease. As more loci are discovered and as more
analysis is done at each identified locus, this proportion of iden-
tified risk will clearly increase substantially.
Conclusions
The 15 years since the identification of the SNCA locus in the
Contursi kindred have seen enormous progress in Parkinson
research to the extent where we now have identified about half
of the risk of developing the disease. What now are our
challenges? Clearly, finding other genes involved in the disease
will, like finding pieces of a jigsaw, help us more clearly see the
whole picture. We need to work out whether all the genes I
have mentioned fit into one puzzle or whether there are two or
more puzzles. a-synuclein and LRRK2 biology is still poorly
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etiology: how are they related? Does the spread of pathology
relate to normal cell biology or is it simply pathological? These
are some of the basic biological questions we need to address.
Identifying genes has also given us the opportunity to identify
people presymptomatically and should help us identify
biomarkers for the disease progression. The last 15 years have
brought enormous progress, but there is still much work to be
done before we can translate this progress into clinical practice.ACKNOWLEDGMENTS
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